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PERANAN PROTEIN ‘DREAM’ DALAM PENGAWALATURAN 
KESAKITAN DI BAWAH ARUHAN FORMALIN PADA TIKUS YANG 
KEKURANGAN TIDUR REM 
  
ABSTRAK 
 
Kekurangan tidur REM telah terbukti mengurangkan paras kesakitan selepas 
beberapa stimulasi kesakitan. Protein ‘Downstream Regulatory Element Antagonist 
Modulator’ (DREAM) merupakan penindas transkripsi bagi gen prodynorphin. 
Kajian ini dijalankan untuk mengkaji perubahan DREAM selepas kekurangan tidur, 
kesakitan dibawah aruhan formalin atau gabungan keduanya, dan perkaitannya 
dengan kelakuan tindak balas kesakitan di bawah aruhan formalin.  Tikus Spraque 
Dawley jantan (250-300 g) dibahagikan kepada empat rawatan utama iaitu bebas 
bergerak tanpa apa-apa rawatan (n=36), kekurangan tidur REM (n=36), kawalan 
tangki (n=36) dan pemulihan tidur (n=36). Kekurangan tidur dirangsangkan selama 
72 jam menggunakan teknik pasu terlangkup. Setiap rawatan utama seterusnya 
dibahagikan kepada dua kumpulan yang tidak atau disuntik dengan formalin 2.5% 
secara subkutan. Kelakuan tindak balas kesakitan dibawah aruhan formalin 
direkodkan selama 1 jam untuk kumpulan yang disuntik formalin. Bahagian 
kompleks ventrobasal talamik,  (VB)  dikeluarkan dari setiap kumpulan untuk 
analisis immunohistokimia (n=6), Western blot (n=6) dan real-time PCR (n=6) 
secara berasingan.  Teknik pasu terlangkup telah disah mengaruhkan kekurangan 
tidur REM dengan memaparkan corak klasik hiperfagia dan kehilangan berat badan 
kepada kumpulan kekurangan tidur REM dan pemulihan tidur. Terdapat kekurangan 
kesakitan yang ketara pada fasa kedua kesakitan di bawah aruhan formalin pada tikus 
 xxv 
yang kekurangan tidur REM. Kekurangan tidur REM mengaruh perubahan 
morfologi dan mengurangkan bilangan neuron yang positif kepada DREAM (DPN) 
pada kedua-dua sisi.  Terdapat peningkatan kepada ekstrak nuklear DREAM. Selepas 
pemulihan tidur selama 72 jam, perubahan kepada DPN tidak kembali ke paras dasar 
serta terdapat pengurangan pada mRNA DREAM di kedua-dua sisi. Kesakitan di 
bawah aruhan formalin mengurangkan bilangan DPN di kedua-dua sisi dan 
peningkatan pada ekstrak DREAM nuklear di sisi kontralateral kepada kedudukan 
suntikan formalin. Kekurangan tidur REM dan ujian formalin meningkatkan DPN, 
ekstrak sitoplasma dan nuklear DREAM pada kedua-dua sisi, di mana peningkatan 
adalah lebih tinggi di sisi kontralateral kecuali pada ekstrak nuclear. Terdapat 
pengurangan pada mRNA DREAM pada sisi ipsilateral. Walaubagaimana pun, 
perubahan tersebut berpotensi untuk dipulihkan kerana tiada perubahan dapat dilihat 
pada DPN, ekstrak DREAM dan mRNA selepas pemulihan tidur. Sebagai 
kesimpulan, kekurangan tidur REM dan kesakitan di bawah aruhan formalin, secara 
berasingan menghasilkan pengaruh tersendiri ke atas DREAM. Walaupun demikian, 
kombinasi kedua-dua rawatan menghasilkan perubahan dinamik intraselular yang 
mencerminkan keupayaan kelangsungan hidup sel neuron, sekurang-kurangnya 
dengan melindungi  fungsi asasnya. Memandangkan protein DREAM bertindak 
sebagai perencat transkripsi gen bagi prodynorphin, keupayaan kelangsungan hidup 
neuron ditunjukkan melalui kekurangan tindak balas kesakitan selepas kekurangan 
tidur REM dan kesakitan di bawah aruhan formalin.  
 
 
 
 
 xxvi 
THE ROLE OF DREAM IN THE REGULATION OF FORMALIN INDUCED 
PAIN IN RAPID EYE MOVEMENT (REM) SLEEP DEPRIVED RATS 
 
ABSTRACT 
 
Rapid eye movement (REM) sleep deprivation has been shown to decrease pain 
threshold after various pain stimuli. Down regulatory antagonist modulator 
(DREAM) is a transcriptional repressor of prodynorphin gene. This study evaluates 
the effect on DREAM in relation to REM sleep deprivation, formalin induced pain or 
combination of both; and its relationship to the formalin induced pain behavioural 
responses. Male Sprague Dawley rats (250-300 g) were divided into four major 
treatments; free moving control (n=36), REM sleep deprivation (n=36), tank control 
(n=36) and sleep recovery (n=36). REM sleep deprivation was elicited for 72 hours 
using the inverted flower pot technique. Each group was further divided into two 
groups which consisted of rats that were either not or subjected to 2.5% formalin 
subcutaneous injection. Food consumption and body weight gain were measured 
before and after the treatments. The formalin induced pain behavioural responses 
were recorded for one hour for rats that subjected to formalin injection. The 
ventrobasal thalamic complex of brain (VB) were removed from each group for 
immunohistochemistry (n=6), Western blot (n=6) and real-time PCR analysis (n=6) 
separately. The ‘inverted flower’ pot technique was confirmed to induce REM sleep 
deprivation in the REM sleep deprived and sleep recovered rats by the classic pattern 
of hyperphagia with converse loss of body weight. There is a marked hypoalgesia 
demonstrated in the second phase of formalin induced pain in the REM sleep 
deprived rats. REM sleep deprivation per se did induce morphological change and 
reduced the number of DREAM positive neurons (DPN) bilaterally. There was an 
 xxvii 
increase in nuclear DREAM extraction bilaterally. After 72 hours sleep recovery, the 
morphological changes still persisted with reduction of the DREAM mRNA 
bilaterally. Formalin induced pain reduced the number of DPN bilaterally and 
increased the nuclear DREAM extraction contralateral to formalin injected site. 
Interestingly, REM sleep deprivation with formalin test increased the number of 
DPN, cytoplasmic and nuclear DREAM extraction bilaterally which was more on the 
contralateral side except for nuclear extraction. There was a significant decrease of 
DREAM mRNA ipsilaterally. However the changes seem to be reversible as no 
change is seen in DPN, DREAM extractions and mRNA in sleep recovery group 
with formalin induced pain. . In conclusion, REM sleep deprivation and formalin 
induced pain per se generated their own distinct effects on DREAM.  Nevertheless, 
the combination of both treatments resulted in dynamic intracellular changes which 
reflected the survival ability of neuronal cells, at least by preserving its basic 
functions. As DREAM is a transcriptional regulator of prodynorphin, the functional 
survivability of the neuronal cells was reflected behaviourally by the significant 
hypoalgesia after both REM sleep deprivation and formalin induced pain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 Introduction 
 
Sleep is an active process and consists of slow wave sleep (SWS) and rapid eye 
movement (REM) sleep. The progression of sleep depends on the activities of the 
wake promoting systems as well as the relative changes in the neurotransmitters of 
the brain. REM sleep is a crucial component of sleep and extensive studies prove that 
lack of REM sleep resulted in morbidities behaviourally (Gulyani & Mallick, 1995, 
Rechtshaffen & Bergmann, 1995, Suchecki et al., 2003) as well as to induce 
intracellular changes such as alteration in intracellular calcium (Ca2+), membrane 
bound ATPase activity, receptor sensitivities and gene expressions (Mallick & 
Gulyani, 1996, Mallick et al., 2000, Majumdar & Mallick, 2003, Terao et al., 2003, 
Koban & Swinson, 2005, Koban et al., 2006, Das & Mallick, 2008). The REM sleep 
induced morbidities reflected how important REM sleep to human and animal is. 
However, the morbidities and intracellular changes are valuable when one is 
conducting a research in relation to REM sleep functions.  
 
Currently, it is understood that while pain disrupts sleep, nevertheless, more 
significantly, sleep deprivation affects pain perception. There have been some studies 
which addressed this issue by specifically studying pain perception changes in 
relation to sleep disturbance in humans (Lentz et al., 1999, Onen et al., 2001). REM 
sleep deprivation induces significant increases in the animal pain behavioural 
responses in certain pain stimuli (Onen et al., 2000, Onen et al., 2001, Hakki Onen et 
 al., 2001, May et al., 2005). However, no molecular study has been conducted to 
clarify these observations which were related to REM sleep and pain. No doubt that 
pain is one of the major public health concerns and understanding pain is important 
in order to improve our decision making skills in relation to pain treatment. Sleep 
deprivation and pain are co-existed in patients who suffered in some major illnesses  
(Okifuji & Hare, 2011). The co-existence of both symptoms results in difficulties in 
term of diagnosing and managing not only the pain but also the illness. Hence, it is 
crucial to understand pain especially in relation to REM sleep by studying the 
molecular mechanisms mediating the interactions between the two factors. Formalin 
test is one of the best animal pain models that can be used to mimic clinical pain. 
Thus, by manipulating formalin induced pain on REM sleep deprived rats, the 
relationship between pain and REM sleep can be clarified.  
 
The recent discovery of down regulatory antagonist modulator (DREAM) 
(Carrión et al., 1999) as a protein that may be involved in pain modulation (Carrión 
et al., 1999, Cheng et al., 2002) has disclosed even more research opportunities 
related to the study of pain. Moreover, previous study has shown that DREAM is a 
transcriptional gene repressor which binds directly to Ca2+ in order to exert its 
intracellular functions (Carrión et al., 1999). As mentioned earlier, REM sleep 
deprivation induces changes in intracellular Ca2+ concentrations (Mallick & Gulyani, 
1996). Due to the facts that Ca2+ is bind directly to DREAM and REM sleep 
deprivation induces the intracellular Ca2+ changes; this study in conducted to 
primarily elucidate the role of DREAM in the regulation of formalin induced pain in 
REM sleep deprived rats. Consequently, the molecular mechanism between pain and 
sleep is delineated by the dynamic changes of intracellular DREAM and DREAM 
 mRNA. The molecular mechanism posed contributes to knowledge and assists any 
other preliminary efforts which are trying to define the cutting edge between sleep 
deprivation and pain. Subsequently, DREAM may be a potential protein marker 
which can be adopted later in clinical setting in order to demarcate causes of sleep 
deprivation, pain or combination of both in a patient. Furthermore, DREAM may 
represent as a potential alternative target for pain management strategies in patients 
with or without sleep deprivation.  
 
1.2 Sleep 
 
Sleep is one of the basic characteristics of all living organisms. It is perceived that 
sleep is a passive state by which living organisms “repress” their activities and 
become “reenergised” for future activities. Sleep is a unique phenomenon where a 
person who is asleep is in a passive state of unconsciousness and when awake, is 
unable to recall any mental activities that occurred while he was asleep. These 
observations lead scientists and philosophers to assume that sleep is a state of rest. 
 
However, sleep is actually an active process.  In mammals, in addition to 
conserving energy, sleep is also involved in other body functions such as a defence 
mechanism against oxidative stress (Everson et al., 2005), facilitating neurogenesis 
(Guzman-Marin et al., 2007, Guzman-Marin et al., 2008), enhancing brain protein 
synthesis (Nakanishi et al., 1997) as well as altering gene expression (O’Hara et al., 
1999, Cirelli et al., 2004, Cirelli et al., 2006). Sleep is characterised by a decrease of 
motor activity with a typical rest posture.  
 The eyes are usually closed and there is muscular hypotonia. At the early stage of 
sleep, mammals are alert to external stimuli but as the sleep deepens the responses 
become less obvious (Datta, 2010).  
 
1.2.1 Studies of sleep patterns 
The electroencephalogram (EEG) of both humans and animals while awake, asleep 
and dreaming, were first defined in the 1930’s (Loomis et al., 1935a,b, Klaue, 1937, 
reviewed in Datta & Maclean, 2007). By studying the EEG patterns in the cat, Klaue 
found that there were two distinct EEG patterns : first was a period of light sleep in 
which there were slow cortical brain waves, followed by a period of deep sleep in  
which the waves sped up (Klaue, 1937, Datta & Maclean, 2007).  
 
It was not until 1953, that the phenomenon of REM sleep was first observed 
in studies of sleep cycles in humans (Aserinsky & Kleitman, 1953) where the eye 
movements, as well as cortical EEG, pulse, respiratory rates and gross body 
movements were recorded in adult subjects (Aserinsky & Kleitman, 1953). It was in 
this study that Aserinsky and Kleitman first discovered REM sleep from observations 
of clusters of jerky, rapid eye movements (REMs), EEG patterns together with the 
increased respiratory and heart rate in sleeping humans (Aserinsky & Kleitman, 
1953). These clusters of REMs appeared in cycles with variation in periods, 
lengthened as the sleep deepened (Aserinsky & Kleitman, 1953) and were related to 
dreams (Dement & Kleitman, 1957). The occurrences of REMs during this particular 
period of sleep resulted in this phase of sleep to be described as the ‘REM sleep' 
phase. 
 
 REM sleep in the animal model was first established in sleeping cats 
(Dement, 1958). Two different patterns of cortical EEG activities were observed, one 
was a low voltage, fast EEG and the other consisted of slow waves and spindles as 
well as some muscle activities in the legs and eyeballs (Dement, 1958). The 
‘paradoxical’ phenomena between EEG and electromyogram (EMG) activities were 
noticed in the same year by Jouvet and Michel as reviewed by Datta and Maclean in 
2007. Subcortical electrodes were implanted and an EEG recording obtained from 
three main areas: the ventral hippocampus, midbrain reticular formation and pontine-
reticularis caudalis nucleus (Datta & Maclean, 2007). Electrodes were also implanted 
in the neck muscles for EMG recording (Datta & Maclean, 2007). The disappearance 
of EMG activities during REM sleep coincided with the increment in awake-like 
EEG activities (Datta & Maclean, 2007). This paradoxical phenomenon was seen 
during REM sleep which was now alternatively known as the ‘paradoxical’ sleep 
phase (Jouvet, 1965).  
 
1.2.2 Types of sleep 
Sleep can be divided into two types: non rapid eye movement (NREM) and REM 
sleep. These sleep stages can be monitored and differentiated by polysomnography 
studies, which consist of electroencephalography, electromyography and 
electrooculography. During wakefulness or sleep, there are some discrepancies in the 
EEG, EMG and electrooculogram (EOG) patterns (Figure 1.1). In a waking state, 
there is low amplitude synchronization of the fast oscillation patterns in the EEG 
(Campbell, 2009) and presence of muscle tone detected by the EMG (Mileva-Seitz et 
al., 2005). During NREM sleep (or slow wave sleep (SWS)), the patterns change 
slowly and the NREM sleep stages can be indentified. 
  In human, there are four stages of NREM sleep (Pizza et al., 2011) (Figure 
1.1). As the sleep deepens, there is high voltage but low frequency wave activity. 
Stage III and IV are the deepest NREM sleep stages and during these stages, only 
low-frequency wave activity is present. The waveforms in stage II are different as it 
is characterised by slow oscillation with distinctive sleep spindles and K-complex (a 
negative sharp wave followed immediately by slower positive component). However, 
in animals there are only two stages of NREM sleep which are stage I and II (Datta 
& Maclean, 2007) (Figure 1.1). During stage I, there is a presence of sleep spindles 
in the cortical EEG. Stage II or deep sleep is identified by the presence of high-
amplitude, low-frequency waves in the cortical EEG.  
 
There are 3 main characteristics that differentiate REM from NREM sleep (Hobson, 
2005): 1) in the cortical EEG, there is low-amplitude synchronization of fast 
oscillations, theta waves; 2) in the EMG, there is very low muscle tone especially in 
antigravity muscles; and 3) in the EOG, there are singlets and clusters of REMs. 
There are also other associated signs such as myotonic twitches, flunctuations in 
cardio-respiratory rhythms and core temperature, penile erection and clitoral 
tumescence.  
 
1.2.3 Wake-promoting systems of the brain 
It is crucial to discuss the wake-promoting systems of the brain in order to 
understand the generation of sleep. The wake-promoting systems are responsible in 
maintaining the alert status of a person.   
           
Figure 1.1: Typical polygraphic appearances showing similarities in behavioural 
state-specific physiological signs across the rat, cat and human.  
Pink: wakefulness, blue: NREM sleep, and yellow: REM sleep (adapted from Datta 
& Maclean, 2007). 
 
 
 
 
 Most of these wake promoting neurons are located in the hypothalamus and the 
brainstem (Murillo-Rodríguez et al., 2009), and produce their own type of 
neurotransmitters (Datta & Maclean, 2007, Murillo-Rodríguez et al., 2009, Datta, 
2010).  
 
In brief, wake-promoting systems consist of some groups of cells that are 
located within the ascending reticular activating system (ARAS). The groups are: 1) 
noradrenergic neurons in locus coeruleus (LC), 2) serotoninergic neurons in raphe 
nucleus (RN), 3) cholinergic neurons in pedunculopontine tegmentum (PPT), 4) 
glutamatergic neurons in midbrain, and 5) dopaminergic neurons in substantia nigra 
compacta (SNc) and ventral tegmental area (VTA) (Sakai & Crochet, 2003, Datta, 
2010). The levels of activity of these groups determine the level of thalamo-cortical 
relay cells that are in ‘ready’ state to transfer the sensory information to the cortex 
(Sakai & Crochet, 2003, Datta, 2010).  
 
1.2.4 Initiation of sleep 
There are many theories related to initiation of sleep. One of the most accepted 
theories is the reticular deactivation theory. In the reticular deactivation theory, it 
was assumed that the waking state requires a certain level of brain activity, and this 
activity is maintained by a steady flow of ascending impulses arising in the brainstem 
reticular formation (Moruzzi, 1972, Datta & Maclean, 2007, Datta, 2010). The 
reduction of these impulses results in sleep.  
 
 
 Recently, Datta and his colleague proposed that a passive process is involved 
in the initiation of sleep. This metabolic homeostasis theory consists of a passive 
process that depends on the homeostatic regulation of the levels of activity-
dependent metabolites (Datta & Maclean, 2007) (Figure 1.2). During wakefulness, 
there is an increase in neuronal activity in the brain which results in an increase in 
endogenous metabolites. The accumulation of metabolites reaches a certain threshold 
and this leads to withdrawal of wakefulness and initiation of sleep (Figure 1.2). The 
withdrawal of wakefulness reduces the rate of metabolite production and the 
accumulated metabolites are cleared from the body, returning it to basal level (Figure 
1.2).  
 
Hence, the oscillation between accumulated and basal metabolites level 
determines the generation between wakefulness and sleep. The metabolites that have 
been recognised to be involved in the generation of sleep are adenosine, γ-
aminobutyric acid (GABA), glycine, prostaglandin D2 (PGD2) and cytokines such as 
interleukin-1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α)  (Datta, 2010). 
 
1.2.5 Neural mechanisms of NREM sleep (or SWS) 
NREM sleep occurs soon after the initiation of sleep. The initiation of NREM sleep 
depends on the activity of wake promoting systems that depends on the neuronal 
activity in thalamo-cortical networks and the level of metabolites in the brain. The 
wake promoting systems together with the level of metabolites are responsible in 
controlling the incoming sensory signals from the thalamus to cerebral cortex (Datta, 
2010).  
 
  
 
 
 
Figure 1.2: Metabolite homeostatic model of physiologic mechanisms for the 
initiation of sleep.  
The oscillations of accumulated and basal metabolites level determine the generation 
between wakefulness and sleep. Red: wakefulness, yellow: sleep (adapted from Datta 
& Maclean, 2007).  
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 The thalamus consists of two types of neurons which differ in function to 
generate NREM sleep: thalamo-cortical relay neurons which relay sensory 
information to the cortex, and thalamic reticular neurons which, when activated, 
prevent thalamo-cortical relay neurons from transferring sensory information to the 
cortex (Steriade et al., 1993, Steriade & Timofeev, 2003, Datta, 2010). During 
NREM sleep generation, the activity of the  wake promoting system is reduced and 
there is an increment of metabolites leading to the excitation of thalamic reticular 
cells and γ-aminobutyric acid-B (GABAB) inhibition of thalamo-cortical relay cells 
(Datta & Maclean, 2007, Datta, 2010). The thalamo-cortical relay cells are 
hyperpolarised by the activity of GABAergic neurons, thus blocking the transmission 
of sensory impulses to the cortex (Datta, 2010). 
 
1.2.6 Neural mechanisms of REM sleep 
The generation of REM sleep is a more complex process compared to NREM sleep. 
In general, the occurrence and intensity of REM sleep depend on the activity of REM 
promoting cell groups. As the REM-promoting neuronal activity reaches a certain 
threshold, the full set of REM signs occurs. The underlying neuronal activity is a 
continuous function. The cholinergic neurotransmitter acetylcholine (ACh) is thought 
to be important in REM sleep production, acting by exciting the populations of 
brainstem reticular formation neurons to produce the set of REM signs. The 
aminergic neurotransmitter serotonin (5-HT) and noradrenaline (NA) are released by 
another neuronal population called REM off neurons (McCarley, 2007) (Figure 1.3). 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.3: The underlying neuronal activity of REM sleep generation is a 
continuous function and involves REM-on and REM-off neurons (reprinted from 
Sleep Medicine, 8(4):302-30, R.W. McCarley, Neurobiology of REM and NREM 
sleep, (page 303), © (2007), with permission from Elsevier). 
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 Recent knowledge on the mechanism of REM sleep generation is explained 
in detail by the cellular-molecular-network (CMN) model of REM sleep regulation 
(Datta & Maclean, 2007, Datta, 2010). As mentioned earlier, REM sleep is 
characterized by a sequence of events, generated by their own distinct group of cells 
located in the pons and midbrain (Table 1.1) (Datta & Maclean, 2007, Datta, 2010). 
These groups of cells that are responsible for generation of REM sleep signs are 
affected by the oscillating changes between cholinergic and aminergic 
neurotransmitters (Datta & Maclean, 2007, Datta, 2010). In order to generate REM 
sleep signs, the groups are excited by the increased level of cholinergic 
neurotransmitter released from the cholinergic neurons in the PPT and lateral dorsal 
tegmentum (LDT) (Datta & Maclean, 2007, Datta, 2010). Consequently, the release 
of aminergic neurotransmitter from the noradrenergic neurons in the LC and 
serotonergic neurons in the RN are reduced or nearly absent (Datta & Maclean, 2007, 
Datta, 2010). 
 
1.2.6.1 The initiation of REM sleep 
During initiation of REM sleep, the increased level of glutamate activates the kainate 
receptors in the cholinergic neurons in PPT and LDT (Datta & Maclean, 2007). This 
event leads to increased release of post-synaptic ACh.  The ACh activates each of the 
groups that generate REM sleep signs and REM sleep inducing site in the medial 
pontine reticular formation (mPRF). While PPT and LDT cholinergic cells are 
activated, the noradrenergic neurons in the LC and serotonergic neurons in the RN 
are inhibited by GABAergic cells located in those areas.   
 
 
 Table 1.1: Cell groups in the brainstem which generate various components of REM 
sleep signs (adapted from Datta & Maclean, 2007).  
 
Cells group in brainstem REM sleep sign 
 Mesencephalic reticular 
formation 
 Medullary magnocellular 
nucleus 
 Cortical EEG activation 
 Locus coerulus alpha  Muscle atonia of postural muscles 
 Periabducens reticular 
formation 
 REMs 
 Caudal-lateral 
peribrachial area 
(predator mammals) 
 Nucleus subcoeruleus 
(prey mammals) 
 Ponto-geniculo-occipital (PGO) spikes in 
occipital cortex 
 Field potentials in the pons (P-wave) 
 Pontis oralis  Hippocampal theta rhythm 
 Parabrachial nucleus  Increase in brain temperature and cardio-
respiratory fluctuations 
 
 
 
 
 
 
 
 
 
 
 This GABA-mediated inhibition of aminergic cells reduces or stops the release of 
aminergic neurotransmitter to the REM sleep sign-induced cells (Datta & Maclean, 
2007, Datta, 2010). 
 
1.2.6.2 The maintenance of REM sleep 
The maintenance and episodes of REM sleep depend on the ratio of cholinergic and 
aminergic neurotransmitters within the cell groups (Datta & Siwek, 2002, Datta & 
Maclean, 2007). In wakefulness or NREM sleep, the ratio of aminergic and 
cholinergic neurotransmitter is 1:1 (Datta, 2010). The activity of aminergic and 
cholinergic neurons is approximately the same during wakefulness, but during 
NREM sleep the activities are equally reduced (Datta, 2010).  
 
During REM sleep, the activity of aminergic neurons is reduced and the 
activity of cholinergic neurons is comparatively high where the ratio is 0:0.65 
(Hobson, 1999, Datta & Siwek, 2002, Datta, 2010).  The activity of cholinergic cells 
in PPT and LDT is maintained by the continuous activation from glutamate that is 
released from the ACh induced mPRF activity (Datta, 2010). The glutamate also 
activates the aminergic and GABAergic cells in the LC and RN; however the 
inhibition of LC and RN precedes the activation of aminergic cells due to the local 
release of GABA in the LC and RN (Datta & Maclean, 2007, Datta, 2010). 
 
 
 
 
 
 1.3 REM sleep deprivation 
 
Sleep is critical for the maintenance of health and support of life. Considerable 
research interests have focused on the selective effects of REM sleep loss and the 
REM sleep deprivation animal model is accepted as a potential useful strategy for 
studying the regulation and functions of REM sleep.  
 
1.3.1 REM sleep deprivation paradigm 
The REM sleep deprivation paradigm can be elicited in animals using a classic 
platform method, which is either a single platform or multiplatform technique. The 
single inverted flower pot technique or platform was first used by Cohen and Dement 
in 1965 on sleep deprived rats (Cohen & Dement, 1965). In this paradigm, the rat is 
placed on a single platform; usually 6.5 cm in size surrounded by a confined tank 
filled with water. The surrounding water is at a specified level such that the rat will 
come into contact with the water when it undergoes REM sleep induced muscle 
atonia. The contact with water awakens the animal, thus preventing the occurrence of 
REM sleep (Tufik et al., 2009). This method has resulted in some morbidity related 
to REM sleep (Tufik, 1981, Seabra & Tufik, 1993, Hoshino, 1996) and it  has been 
shown that during REM sleep deprivation, the NREM sleep loss is minimum 
(Machado et al., 2005). 
 
In a multiplatform paradigm, a rat is placed inside a large water tank that 
contains several platforms (Van Hulzen & Coenen, 1981). The presence of more than 
one platform reduces the movement restriction and allows the rat to ambulate (Van 
Hulzen & Coenen, 1981).  
 Even though the multiplatform paradigm does exclude immobilization stress, it does 
not however, exclude stress due to social isolation. Hence, a modified multiplatform 
technique is carried out in order to minimise the social isolation induced stress.  
 
The modified multiplatform technique involves many disposable platforms 
and suppresses sleep simultaneously in a group of rats (Suchecki et al., 2000, 
Suchecki & Tufik, 2000, Machado et al., 2004, Machado et al., 2005). Interestingly, 
this technique results in more stress than the single platform method. At the same 
time, the occurrences of sleep episodes in the modified multiplatform technique were 
lower than in the single platform method (Medeiros et al., 1998). Nevertheless, 
socially induced awakenings and the social interactions induced between the rats in 
the tank caused a significant increase in the awakening time (Medeiros et al., 1998).  
 
In order to study chronic sleep deprivation, a method called disk-over-water 
(DOW) method was designed (Rechtschaffen & Bergmann, 1995). An experimental 
rat was placed on one side of a divided horizontal disk that was suspended over a 
shallow tray of 2 to 3 cm deep water (Rechtschaffen & Bergmann, 1995). EEG, 
EMG and theta activity were continuously monitored to detect sleep states 
(Rechtschaffen & Bergmann, 1995).  When the rat started to sleep, the disk was 
automatically rotated at low speed, awakening the rat and forcing it to walk in an 
opposite direction to the disk rotation in order to avoid falling into the water 
(Rechtschaffen & Bergmann, 1995). This method has been shown to selectively 
deprive REM sleep by 99 % (Kushida et al., 1989, Rechtschaffen & Bergmann, 
1995) and 86 % (Landis et al., 1992, Rechtschaffen & Bergmann, 1995).  
 
 Nevertheless, the main issue here is how to exclude the stress that may be 
generated during these deprivation methods, which can be the causative factor of the 
REM sleep deprivation induced co-morbidities. Stress induced by social isolation in 
animals exposed to the single platform technique increases the plasma 
adrenocorticotropic hormone (ACTH) (Suchecki et al., 1998), plasma corticosterone 
(Suchecki et al., 1998) as well as aggressiveness (Gulyani & Mallick, 1995). It has 
been shown that immobilisation induced sleep changes which could interrupt not 
only REM, but also NREM sleep (Pawlyk et al., 2008).  
 
In a multiplatform paradigm, it has been shown that there was an increase in 
the weight of the adrenal gland and a reduction in the thymus weight due to stress 
(Coenen & van Luijtelaar, 1985). The multiplatform technique reduces the social 
isolation and locomotor restrictions but the forced awakening secondary to social 
interactions results in stress with an associated increase of plasma corticosterone and 
ACTH levels (Suchecki et al., 1998, Suchecki et al., 2000). Interestingly, in the large 
multiplatform technique the ACTH levels of the rats were elevated even though it 
was not as high as in rats exposed to the small multiplatforms (Suchecki et al., 1998). 
Hence, the social interactions per se in the water tank can generate some form of 
stress.  
 
1.3.2 Morbidities related to REM sleep deprivation paradigm 
 
1.3.2.1 Morbidities related to animal behaviours 
Significant morbidities developed when animals were exposed to REM sleep 
deprivation. These symptoms: debilitated appearance (Rechtshaffen & Bergmann, 
 1995), aggressive behaviour (Gulyani & Mallick, 1995), hyperphagia (Rechtshaffen 
& Bergmann, 1995, Suchecki et al., 2003, Hipólide et al., 2006, Koban et al., 2008), 
weight loss (Rechtshaffen & Bergmann, 1995, Suchecki et al., 2003, Hipólide et al., 
2006, Koban et al., 2008), elevated metabolic rate (Koban & Swinson, 2005), 
elevated energy expenditure, increased plasma catecholamines, hypothyroidism, 
reduced core temperature (Rechtshaffen & Bergmann, 1995) and reduced levels of 
anabolic hormones (Everson & Crowley, 2004) are consistent and some are 
reproducible. These morbidities are harmful but at the same time useful as an 
alternative to assess if the inverted flower pot technique was able to produce rats that 
were selectively REM sleep deprived. 
 
One of the most important characteristics of REM sleep deprivation is that 
REM sleep deprived rats developed a degree of hyperphagia that was conversely 
associated with a loss of body weight (Rechtshaffen & Bergmann, 1995, Suchecki et 
al., 2003, Koban & Swinson, 2005, Hipólide et al., 2006, Koban & Stewart, 2006, 
Koban et al., 2008, Galvão et al., 2009). Most studies have demonstrated changes in 
neuropeptide Y (NPY), pro-opiomelanocortin (POMC) and leptin (Koban & 
Swinson, 2005, Koban et al., 2006), in accordance with hyperphagia after REM sleep 
deprivation.  
 
It has been known that hypothalamic NPY, POMC and leptin are the 
components of food intake regulation (Koban & Swinson 2005, Koban et al., 2006). 
The NPY gene expression was markedly increased within the hypothalamus (Koban 
et al., 2006) with a pronounced decrease in POMC gene expression (Koban et al., 
2006), the counterpart to NPY.  
 In a study, serum leptin decreased more than 50 percent in rats which demonstrated 
hyperphagia and lost of body weight after 5 days of REM sleep deprivation (Koban 
& Swinson, 2005).  
 
It has been shown that the body weight loss despite the hyperphagia is a 
result of an increase in resting metabolic rate in REM sleep deprived rats (Koban & 
Swinson, 2005). This hypermetabolic state is said to be mediated via Uncoupling 
Protein 1 (UCP1) in brown adipose tissue (Koban & Swinson, 2005). UCP1 is a 32 
kDa inner mitochondrial membrane protein that plays a major role in cellular 
respiration by allowing proton leakage. The movement of protons resulted in 
thermodynamic energy which dissipated as heat rather than adenosine-5'-
triphosphate (ATP) formation. This resulted in a hypermetabolic state with an 
associate weight loss despite the hyperphagia.  REM sleep deprivation also leads to 
increased energy expenditure.  
 
REM sleep deprived rats showed increased use of fats and proteins but with a 
normal glucose uptake (Rechtschaffen & Bergmann, 1995). Other studies have also 
confirmed that it was the accelerated use of fat that resulted in the loss of body 
weight (Hipólide et al., 2006). Studies have also shown that the increased energy loss 
was not due to increased waste products or weight loss from dehydration (Bergmann 
et al., 1989).  
 
1.3.2.2 Morbidities related to morphological neuronal changes 
The morphology of neuronal induced REM sleep deprivation changes has been 
specifically studied since more than a century ago. As quoted by Majumdar and 
 Mallick 2005, back in 1912, Pieron described the neuronal morphological changes 
due to REM sleep deprivation as ‘become shrunken, the nucleus moving to 
periphery, joining the cell membrane. The nucleolus is also generally ectopic. There 
is vacuolization of the protoplasm, the cell seeming to proceed to autophagy’. The 
author also mentioned fragmentation and the disappearance of Nissl neurofibrillae 
(Pieron, 1912, Majumdar & Mallick, 2005).  
 
Recent studies served to further confirm that neuronal morphology and 
structure were both affected by REM sleep deprivation (Majumdar & Mallick, 2005). 
It was observed that after REM sleep deprivation the size of the neurons in rat brain 
cells were reduced and the changes were dependent on the physiological function 
and neurotransmitter content of the neuronal cells (Majumdar & Mallick, 2005). 
Further studies confirmed that neuronal apoptosis occurred within the brain after 6 
days of REM sleep deprivation (Biswas et al., 2006).  
 
1.3.3 REM sleep deprivation and pain 
Many studies have been conducted to observe the effects of REM sleep deprivation 
on various pain modalities (Hakki Onen et al., 2001, May et al., 2005). In animals, 
REM sleep deprivation has been shown to induce a significant increase in the pain 
behaviour responses to mechanical (Hakki Onen et al., 2001), thermal (Hakki Onen 
et al., 2001, May et al., 2005) and electrical noxious stimuli in rats (Hakki Onen et 
al., 2001) but no significant differences have been found in the reaction to formalin 
noxious stimuli (Hakki Onen et al., 2001).  
 
 
 1.4 Pain 
 
The International Association for the Study of Pain (IASP) has defined pain as a 
sensory and emotional experience associated with real or potential injuries, or 
described in terms of such injuries (Merskey & Bogduk, 1994). Pain is an 
‘unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage’ (Loeser & Melzack, 1999).  
 
1.4.1 Mechanisms of pain 
In general, pain information is transmitted through peripheral nerve endings to the 
spinal cord, than carried by ascending tracts to the thalamus and primary 
somatosensory (SI) cortex. 
 
1.4.1.1 Nociceptors 
Nociceptor is a word from Latin nocere, meaning ‘to hurt’ (Bear et al., 2007). 
Nociceptors are peripheral receptors widely found in peripheral organs such as skin. 
Structurally, nociceptors are free nerve endings and represent the more distal part of 
a first-order peripheral afferent fibre (Almeida et al., 2004). In general, there are two 
general nociceptors: mechanical or thermal nociceptors and polymodal nociceptors 
(Nadeu et al., 2004, Bear et al., 2007).  
 
The mechanical or thermal nociceptors transmit localised pain sensations to 
the central nervous system via the peripheral afferent fibres, Aδ fibres. The 
polymodal nociceptors respond to exogenous chemical stimuli (e.g. formalin, 
carrageenan), endogenous chemical stimuli (e.g. bradykinin, histamine) and thermal 
 stimuli and transmit to the central nervous system via another type of peripheral 
afferent fibre called C fibre (Nadeu et al., 2004). There is another fibre, Aβ fibre 
which is not responsive to noxious stimulus in normal conditions (Almeida et al., 
2004). 
 
1.4.1.2 First order afferent fibres 
First order afferent fibres are classified in accordance to their structure, diameter, and 
conduction velocity. Aδ fibres which are myelinated, have a diameter from 2.0 to 6.0 
µm and conduction velocity of 12-30 m/s. C fibres are unmyelinated, ranging in 
diameter from 0.4 to 1.2 µm and having a velocity of 0.5 – 2.0 m/s. There are also 
Aβ fibres which are myelinated, with a diameter of more than 10 µm and a velocity 
of 30-100 m/s and do not propagate noxious potentials in normal situations (Millan, 
1999, Almeida et al., 2004, Schaible, 2007). Hence, the C fibres are the smallest and 
with the slowest conduction velocity and the Aβ fibres are the largest and fastest 
fibres, with the Aδ fibres being the intermediate between the two. 
 
First order afferent fibres respond to the specific stimuli that activate the 
receptive field of the respective receptors. The Aδ fibres are classified into two 
groups: type I and II. The type I of Aδ fibres has mechanoreceptors that respond to 
thermal or chemical stimuli. Type II are fibres with mechanothermal receptors that 
respond to high temperatures (45-53 ºC) and some receptors for intense cold (-15 ºC) 
and later sensitized to vigorous mechanical stimuli at nonnoxious threshold (Millan, 
1999, Almeida et al., 2004, Schaible, 2007).  
 
 There are three types of C fibres. These subtypes are different in terms of 
their responses to certain stimuli via their related nociceptors. One type of the C 
fibres is activated by tissue damage via its polymodal nociceptors. Another type of 
the C fibres is involved in detection of the burning sensation via its mechanosensitive 
nociceptors.  The third type is the C fibres which respond to the presence of 
inflammation, detected by silent receptors, a group of receptors which does not 
respond to noxious stimuli in general (Millan, 1999, Almeida et al., 2004, Schaible, 
2007). 
 
1.4.1.3 The spinal cord organization 
The primary afferent fibres reach the spinal cord via the dorsal root ganglion, 
organize themselves in the ventrolateral bundle of roots, become part of Lissauer 
Tract and synapse with the second order neurons. The second order neurons are 
distributed along the dorsal horn of the spinal cord and are organized according to 
the Rexed laminae (Almeida et al., 2004, Bear et al., 2007). The dorsal horn of the 
spinal cord consists of neurons that become the second order afferent fibres and 
ascending pathways originating from the spinal cord; as well as the intrinsic neurons 
which interact with the afferent and efferent nociceptive stimuli (Almeida et al., 
2004).   
 
There are three distinct groups of neurons that become the ascending 
pathways: the specific nociceptive (SN), wide dynamic range (WDR) and non 
nociceptive (N-NOC) neurons. The SN neurons respond exclusively to noxious 
stimuli from Aδ and C fibres. They are in laminae I (somatotropic organization), II 
(external), V and VI (Almeida et al., 2004). The WDR neurons respond to 
 mechanical, thermal and chemical stimuli coming from Aδ, C and Aβ fibres and 
found in lamina I, II (external), IV, V, VI, X and in the anterior horn. The N-NOC 
neurons respond to innocuous stimuli (Millan, 1999, Almeida et al., 2004).  
 
1.4.1.4 Afferent nociceptive pathways of the spinal cord 
After the interactions, the axons of the second order afferent fibres become part of 
the anterolateral fascicle or posterior fascicle forming afferent bundles that transmit 
the nociceptive impulse to the brain including among others, the thalamus, 
periaqueductal substance, parabrachial region and reticular formation of the medulla 
(Almeida et al., 2004).  
 
The afferent bundles that transmit the sensory impulse to the thalamus are 
called the spinothalamic tract. There are three forms of spinothalamic tract. The first 
is the ventral spinothalamic tract which directly projects to the nuclei of the lateral 
complex of the thalamus involved in the sensory-discriminative component of pain. 
The dorsal spinothalamic tract projects to the nuclei of the posterior medial and 
intralaminar complex of the thalamus and is involved in the motivational-affective 
aspects of pain. Finally, another spinothalamic pathway projects directly to the 
medial central nucleus of the thalamus and is involved in the affective component of 
the painful experience (Almedia et al., 2004). Most of the cells project to the 
contralateral thalamus although a small fraction projects ipsilaterally (Willis & 
Westlund, 1997). 
 
 
 
